Literature DB >> 12766571

Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography.

J A H Droste1, C P W G M Verweij-Van Wissen, D M Burger.   

Abstract

A reversed-phase high-performance liquid chromatography method for the simultaneous quantitative determination of the currently available HIV protease inhibitors amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, the active nelfinavir metabolite M8, and the nonnucleoside reverse transcriptase inhibitor nevirapine in human plasma is described. The method involved liquid-liquid extraction from plasma, followed by high-performance liquid chromatography with an OmniSpher 5 C18 column and ultraviolet detection set at a wavelength of 215 nm for the protease inhibitors and 280 nm for nevirapine. The runtime was 25 minutes. The assay has been validated over the concentration range of 0.05 to 30 mg/L for indinavir, nelfinavir, ritonavir, and saquinavir, 0.07 to 30 mg/L for amprenavir and lopinavir, and 0.05 to 15 mg/L for M8 and nevirapine. This method proved to be simple, accurate, and precise and is useful for the therapeutic drug monitoring of protease inhibitors and the nonnucleoside reverse transcriptase inhibitor nevirapine on a routine basis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12766571     DOI: 10.1097/00007691-200306000-00023

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  27 in total

1.  A chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in Thailand.

Authors:  Nirun Vanprapar; Tim R Cressey; Kulkanya Chokephaibulkit; Petronella Muresan; Nottasorn Plipat; Virat Sirisanthana; Wasana Prasitsuebsai; Suchat Hongsiriwan; Tawee Chotpitayasunondh; Achara Eksaengsri; MariPat Toye; Mary Elizabeth Smith; Kenneth McIntosh; Edmund Capparelli; Ram Yogev
Journal:  Pediatr Infect Dis J       Date:  2010-10       Impact factor: 2.129

2.  The effect of the CYP2C19*2 heterozygote genotype on the pharmacokinetics of nelfinavir.

Authors:  David M Burger; H Reinier Schwietert; E P H Colbers; Mark Becker
Journal:  Br J Clin Pharmacol       Date:  2006-08       Impact factor: 4.335

3.  Atazanavir pharmacokinetics with and without tenofovir during pregnancy.

Authors:  Mark Mirochnick; Brookie M Best; Alice M Stek; Edmund V Capparelli; Chengcheng Hu; Sandra K Burchett; Steven S Rossi; Elizabeth Hawkins; Michael Basar; Elizabeth Smith; Jennifer S Read
Journal:  J Acquir Immune Defic Syndr       Date:  2011-04-15       Impact factor: 3.731

4.  UPLC-MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissues.

Authors:  Jiangeng Huang; Nagsen Gautam; Sai Praneeth R Bathena; Upal Roy; JoEllyn McMillan; Howard E Gendelman; Yazen Alnouti
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2011-07-01       Impact factor: 3.205

5.  Immunochromatographic strip test for rapid detection of nevirapine in plasma samples from human immunodeficiency virus-infected patients.

Authors:  Tim R Cressey; Sawitree Nangola; Yardpiroon Tawon; Mookda Pattarawarapan; Marc Lallemant; Chatchai Tayapiwatana
Journal:  Antimicrob Agents Chemother       Date:  2007-07-02       Impact factor: 5.191

6.  Early postpartum pharmacokinetics of lopinavir initiated intrapartum in Thai women.

Authors:  Tim R Cressey; Russell Van Dyke; Gonzague Jourdain; Thanyawee Puthanakit; Anuvat Roongpisuthipong; Jullapong Achalapong; Prapap Yuthavisuthi; Sinart Prommas; Nantasak Chotivanich; Robert Maupin; Elizabeth Smith; David E Shapiro; Mark Mirochnick
Journal:  Antimicrob Agents Chemother       Date:  2009-02-23       Impact factor: 5.191

7.  Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals.

Authors:  Laura Dickinson; Marta Boffito; David J Back; Saye H Khoo; Anton L Pozniak; Peter Mugyenyi; Concepta Merry; Reshma Saskia Autar; David M Burger; Leon J Aarons
Journal:  J Antimicrob Chemother       Date:  2008-09-29       Impact factor: 5.790

8.  Ultra-fast analysis of plasma and intracellular levels of HIV protease inhibitors in children: a clinical application of MALDI mass spectrometry.

Authors:  Jeroen J A van Kampen; Mariska L Reedijk; Peter C Burgers; Lennard J M Dekker; Nico G Hartwig; Ineke E van der Ende; Ronald de Groot; Albert D M E Osterhaus; David M Burger; Theo M Luider; Rob A Gruters
Journal:  PLoS One       Date:  2010-07-01       Impact factor: 3.240

9.  Ultrafast and high-throughput mass spectrometric assay for therapeutic drug monitoring of antiretroviral drugs in pediatric HIV-1 infection applying dried blood spots.

Authors:  Roland J W Meesters; Jeroen J A van Kampen; Mariska L Reedijk; Rachel D Scheuer; Lennard J M Dekker; David M Burger; Nico G Hartwig; Albert D M E Osterhaus; Theo M Luider; Rob A Gruters
Journal:  Anal Bioanal Chem       Date:  2010-07-15       Impact factor: 4.142

10.  Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure.

Authors:  Weerawat Manosuthi; Sasisopin Kiertiburanakul; Wannarat Amornnimit; Wisit Prasithsirikul; Supeda Thongyen; Samruay Nilkamhang; Kiat Ruxrungtham; Somnuek Sungkanuparph
Journal:  AIDS Res Ther       Date:  2009-12-23       Impact factor: 2.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.